Log In
Print
BCIQ
Print
Print this Print this
 

Anti-vWF Nanobody, caplacizumab (ALX-0081/ALX-0681)

  Manage Alerts
Collapse Summary General Information
Company Ablynx N.V.
DescriptionNanobodies targeting von Willebrand factor (vWF)
Molecular Target von Willebrand factor (vWF)
Mechanism of Actionvon Willebrand factor (vWF) inhibitor; Antibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase II
Standard IndicationThrombocytopenia
Indication DetailsTreat thrombotic thrombocytopenic purpura (TTP)
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today